These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 8070004

  • 1. Phase I and pharmacokinetics studies of prochlorperazine 2-h i.v. infusion as a doxorubicin-efflux blocker.
    Sridhar KS, Krishan A, Samy TS, Duncan RC, Sauerteig A, McPhee GV, Auguste ME, Benedetto PW.
    Cancer Chemother Pharmacol; 1994; 34(5):377-84. PubMed ID: 8070004
    [Abstract] [Full Text] [Related]

  • 2. Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies.
    Sridhar KS, Krishan A, Samy TS, Sauerteig A, Wellham LL, McPhee G, Duncan RC, Anac SY, Ardalan B, Benedetto PW.
    Cancer Chemother Pharmacol; 1993; 31(6):423-30. PubMed ID: 8453681
    [Abstract] [Full Text] [Related]

  • 3. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
    Raschko JW, Synold TW, Chow W, Coluzzi P, Hamasaki V, Leong LA, Margolin KA, Morgan RJ, Shibata SI, Somlo G, Tetef ML, Yen Y, ter Veer A, Doroshow JH.
    Cancer Chemother Pharmacol; 2000; 46(5):403-10. PubMed ID: 11127945
    [Abstract] [Full Text] [Related]

  • 4. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, DeAngelis C, Bunting P.
    Cancer Res; 1993 Oct 15; 53(20):4837-42. PubMed ID: 8402670
    [Abstract] [Full Text] [Related]

  • 5. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
    de Jong J, Geijssen GJ, Munniksma CN, Vermorken JB, van der Vijgh WJ.
    J Clin Oncol; 1992 Dec 15; 10(12):1897-906. PubMed ID: 1453205
    [Abstract] [Full Text] [Related]

  • 6. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Négrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C.
    Cancer Chemother Pharmacol; 1998 Dec 15; 41(4):281-91. PubMed ID: 9488597
    [Abstract] [Full Text] [Related]

  • 7. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion.
    Muller C, Chatelut E, Gualano V, De Forni M, Huguet F, Attal M, Canal P, Laurent G.
    Cancer Chemother Pharmacol; 1993 Dec 15; 32(5):379-84. PubMed ID: 8339389
    [Abstract] [Full Text] [Related]

  • 8. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
    Tolcher AW, O'Shaughnessy JA, Weiss RB, Zujewski J, Myhand RC, Schneider E, Hakim F, Gress R, Goldspiel B, Noone MH, Brewster LR, Gossard MR, Cowan KH.
    Clin Cancer Res; 1997 May 15; 3(5):755-60. PubMed ID: 9815746
    [Abstract] [Full Text] [Related]

  • 9. Slow infusion for the prevention of akathisia induced by prochlorperazine: a randomized controlled trial.
    Vinson DR, Migala AF, Quesenberry CP.
    J Emerg Med; 2001 Feb 15; 20(2):113-9. PubMed ID: 11207403
    [Abstract] [Full Text] [Related]

  • 10. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin.
    Schwartz GK, Ward D, Saltz L, Casper ES, Spiess T, Mullen E, Woodworth J, Venuti R, Zervos P, Storniolo AM, Kelsen DP.
    Clin Cancer Res; 1997 Apr 15; 3(4):537-43. PubMed ID: 9815717
    [Abstract] [Full Text] [Related]

  • 11. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG, Armand JP, Terret C, de Forni M, Abigerges D, Winograd B, Igwemezie L, Schacter L, Kaul S, Ropers J, Bonnay M.
    J Clin Oncol; 1996 Jul 15; 14(7):2020-30. PubMed ID: 8683232
    [Abstract] [Full Text] [Related]

  • 12. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J, Limacher JM, Levêque D, Duclos B, Dufour P, Bergerat JP, Methlin G.
    Bull Cancer; 1997 Jun 15; 84(6):603-8. PubMed ID: 9295863
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA, Doig RG, Sobol MM, Watson DM, Sheridan WP, Morstyn G, Mihaly G, Green MD.
    Cancer Res; 1990 Aug 15; 50(16):5095-101. PubMed ID: 2379173
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
    Lopes de Menezes DE, Mayer LD.
    Cancer Chemother Pharmacol; 2002 Jan 15; 49(1):57-68. PubMed ID: 11855753
    [Abstract] [Full Text] [Related]

  • 15. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997 Jan 15; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

  • 16. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
    Berg SL, Blaney SM, Adamson PC, O'Brien M, Poplack DG, Arndt C, Blatt J, Balis FM.
    J Clin Oncol; 1998 Jan 15; 16(1):181-6. PubMed ID: 9440741
    [Abstract] [Full Text] [Related]

  • 17. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
    Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A.
    J Clin Oncol; 1995 Jul 15; 13(7):1777-85. PubMed ID: 7602367
    [Abstract] [Full Text] [Related]

  • 18. Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.
    Conley BA, Egorin MJ, Whitacre MY, Carter DC, Zuhowski EG, Van Echo DA.
    Cancer Chemother Pharmacol; 1993 Jul 15; 33(2):107-12. PubMed ID: 8261569
    [Abstract] [Full Text] [Related]

  • 19. Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy.
    Morgan RJ, Synold T, Carr BI, Doroshow JH, Womack EP, Shibata S, Somlo G, Raschko J, Leong L, McNamara M, Chow W, Tetef M, Margolin K, Akman S, Longmate J.
    Cancer Chemother Pharmacol; 2001 Apr 15; 47(4):327-32. PubMed ID: 11345649
    [Abstract] [Full Text] [Related]

  • 20. Phase I trial of cremophor EL with bolus doxorubicin.
    Millward MJ, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JF, Olver IN, Linahan BM, Linsenmeyer ME, Woodcock DM.
    Clin Cancer Res; 1998 Oct 15; 4(10):2321-9. PubMed ID: 9796961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.